IN2014CN00568A - - Google Patents
Info
- Publication number
- IN2014CN00568A IN2014CN00568A IN568CHN2014A IN2014CN00568A IN 2014CN00568 A IN2014CN00568 A IN 2014CN00568A IN 568CHN2014 A IN568CHN2014 A IN 568CHN2014A IN 2014CN00568 A IN2014CN00568 A IN 2014CN00568A
- Authority
- IN
- India
- Prior art keywords
- compounds
- therapy
- formula
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1114103.3A GB201114103D0 (en) | 2011-08-17 | 2011-08-17 | Novel compounds |
PCT/EP2012/065918 WO2013024104A1 (en) | 2011-08-17 | 2012-08-15 | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN00568A true IN2014CN00568A (de) | 2015-04-03 |
Family
ID=44764570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN568CHN2014 IN2014CN00568A (de) | 2011-08-17 | 2012-08-15 |
Country Status (37)
Country | Link |
---|---|
US (4) | US9067936B2 (de) |
EP (2) | EP3150601A1 (de) |
JP (1) | JP6059723B2 (de) |
KR (1) | KR20140064878A (de) |
CN (1) | CN103889984B (de) |
AR (1) | AR087545A1 (de) |
AU (1) | AU2012296914B2 (de) |
BR (1) | BR112014003681A8 (de) |
CA (1) | CA2843537A1 (de) |
CL (1) | CL2014000365A1 (de) |
CO (1) | CO6862151A2 (de) |
CR (1) | CR20140076A (de) |
CY (1) | CY1118370T1 (de) |
DK (1) | DK2744809T3 (de) |
DO (1) | DOP2014000031A (de) |
EA (1) | EA023374B1 (de) |
ES (1) | ES2609857T3 (de) |
GB (1) | GB201114103D0 (de) |
HR (1) | HRP20161674T1 (de) |
HU (1) | HUE030106T2 (de) |
IL (1) | IL230489A (de) |
IN (1) | IN2014CN00568A (de) |
JO (1) | JO3187B1 (de) |
LT (1) | LT2744809T (de) |
ME (1) | ME02589B (de) |
MX (1) | MX350597B (de) |
MY (1) | MY170729A (de) |
PE (1) | PE20141406A1 (de) |
PL (1) | PL2744809T3 (de) |
PT (1) | PT2744809T (de) |
RS (1) | RS55560B1 (de) |
SI (1) | SI2744809T1 (de) |
SM (1) | SMT201700005B (de) |
TW (1) | TWI558704B (de) |
UA (1) | UA110838C2 (de) |
UY (1) | UY34264A (de) |
WO (1) | WO2013024104A1 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2721031B1 (de) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomainhemmer und ihre verwendungen |
GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
MX2015012005A (es) * | 2013-03-11 | 2016-04-04 | Abbvie Inc | Inhibidores de bromodominio. |
JP2016516701A (ja) | 2013-03-11 | 2016-06-09 | アッヴィ・インコーポレイテッド | 縮合四環系ブロモドメイン阻害剤 |
EP2970312B1 (de) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet-bromdomänenhemmer und therapeutische verfahren damit |
KR102355670B1 (ko) | 2013-03-15 | 2022-02-08 | 인사이트 홀딩스 코포레이션 | Bet 단백질 저해제로서의 삼환식 복소환 |
TWI530499B (zh) * | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類 |
SG10201710705UA (en) | 2013-06-21 | 2018-02-27 | Zenith Epigenetics Ltd | Novel bicyclic bromodomain inhibitors |
US9662311B2 (en) | 2013-06-21 | 2017-05-30 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
EP3027604B1 (de) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Neuartige chinazolinone als bromdomänenhemmer |
WO2015049629A1 (en) * | 2013-10-01 | 2015-04-09 | Piramal Enterprises Limited | Imidazoquinoline compounds as bromodomain inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015095492A1 (en) * | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
HUE043441T2 (hu) | 2014-06-20 | 2019-08-28 | Constellation Pharmaceuticals Inc | 2-((4S)-6-(4-klórfenil)-l-metil-4H-benzo[c]izoxazolo[4,5-e]azepin-4-il)acetamid kristályos formái |
ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
EP3233846A4 (de) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitoren von bromdomänen |
EP3253756B1 (de) | 2015-02-03 | 2021-09-22 | Trillium Therapeutics Inc. | Fluorierte imidazo[4,5-c]chinolin-derivate als inhibitoren von bromodomainhaltigen proteinen |
US10307407B2 (en) | 2015-02-27 | 2019-06-04 | The Regents Of The University Of Michigan | 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors |
GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
WO2016186453A1 (en) * | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
WO2016199943A1 (en) * | 2015-06-11 | 2016-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
CN108290856A (zh) | 2015-08-11 | 2018-07-17 | 尼奥迈德研究所 | 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途 |
US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
IL257340B2 (en) | 2015-08-12 | 2023-10-01 | Neomed Inst | Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals |
WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
AU2017219627B2 (en) | 2016-02-15 | 2021-08-05 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors |
EP3440082A1 (de) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunktionelle zwischenprodukte für den ligandenabhängigen zielproteinabbau |
EP3440066B1 (de) | 2016-04-06 | 2022-11-30 | The Regents of The University of Michigan | Mdm2 protein abbauer |
MX2018012379A (es) | 2016-04-12 | 2019-07-04 | Univ Michigan Regents | Degradadores de proteinas de bromodominio y dominioextraterminal (bet). |
DK3472157T3 (da) | 2016-06-20 | 2023-05-01 | Incyte Corp | Krystallinske faste former af en bet-inhibitor |
US11466028B2 (en) | 2016-09-13 | 2022-10-11 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as BET protein degraders |
US10975093B2 (en) | 2016-09-13 | 2021-04-13 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as BET protein degraders |
WO2018144789A1 (en) | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
US11267822B2 (en) | 2017-09-13 | 2022-03-08 | The Regents Of The University Of Michigan | BET bromodomain protein degraders with cleavable linkers |
CN108033957A (zh) * | 2018-01-09 | 2018-05-15 | 中国药科大学 | 一种喹啉类BET bromodomain抑制剂及其制备方法和用途 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022132049A1 (en) * | 2020-12-17 | 2022-06-23 | National University Of Singapore | Treating cancers using bet inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
NZ540826A (en) | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
DK1699512T3 (da) | 2003-11-03 | 2012-09-17 | Glaxo Group Ltd | Fluiddispenseringsindretning |
ES2308272T3 (es) | 2003-11-21 | 2008-12-01 | Novartis Ag | Derivados de 1h-imidazoquinolina como inhibidores de la proteina quinasa. |
US8658666B2 (en) | 2005-02-11 | 2014-02-25 | 3M Innovative Properties Company | Substituted imidazoquinolines and imidazonaphthyridines |
BRPI0616338A2 (pt) | 2005-09-23 | 2011-06-14 | Coley Pharm Group Inc | mÉtodo para 1h-imidazo[4,5-c] piridinas e anÁlogos da mesma |
JP2009519955A (ja) | 2005-12-16 | 2009-05-21 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 置換されたイミダゾキノリン、イミダゾナフチリジンおよびイミダゾピリジン、組成物ならびに方法 |
JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2ブロモドメイン結合剤 |
US8476260B2 (en) * | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
ES2564318T3 (es) * | 2009-11-05 | 2016-03-21 | Glaxosmithkline Llc | Inhibidor de bromodominio de benzodiazepina |
GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB201106799D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
-
2011
- 2011-08-17 GB GBGB1114103.3A patent/GB201114103D0/en not_active Ceased
-
2012
- 2012-08-15 WO PCT/EP2012/065918 patent/WO2013024104A1/en active Application Filing
- 2012-08-15 CA CA2843537A patent/CA2843537A1/en not_active Abandoned
- 2012-08-15 UA UAA201400590A patent/UA110838C2/uk unknown
- 2012-08-15 JO JOP/2012/0229A patent/JO3187B1/ar active
- 2012-08-15 PL PL12748028T patent/PL2744809T3/pl unknown
- 2012-08-15 IN IN568CHN2014 patent/IN2014CN00568A/en unknown
- 2012-08-15 RS RS20170014A patent/RS55560B1/sr unknown
- 2012-08-15 CN CN201280040092.5A patent/CN103889984B/zh not_active Expired - Fee Related
- 2012-08-15 EA EA201490200A patent/EA023374B1/ru not_active IP Right Cessation
- 2012-08-15 AU AU2012296914A patent/AU2012296914B2/en not_active Ceased
- 2012-08-15 MY MYPI2014700328A patent/MY170729A/en unknown
- 2012-08-15 TW TW101129613A patent/TWI558704B/zh not_active IP Right Cessation
- 2012-08-15 LT LTEP12748028.3T patent/LT2744809T/lt unknown
- 2012-08-15 EP EP16192662.1A patent/EP3150601A1/de not_active Withdrawn
- 2012-08-15 ME MEP-2016-288A patent/ME02589B/de unknown
- 2012-08-15 KR KR1020147007082A patent/KR20140064878A/ko not_active Application Discontinuation
- 2012-08-15 BR BR112014003681A patent/BR112014003681A8/pt not_active Application Discontinuation
- 2012-08-15 MX MX2014001834A patent/MX350597B/es active IP Right Grant
- 2012-08-15 JP JP2014525437A patent/JP6059723B2/ja not_active Expired - Fee Related
- 2012-08-15 ES ES12748028.3T patent/ES2609857T3/es active Active
- 2012-08-15 PT PT127480283T patent/PT2744809T/pt unknown
- 2012-08-15 SI SI201230818A patent/SI2744809T1/sl unknown
- 2012-08-15 DK DK12748028.3T patent/DK2744809T3/en active
- 2012-08-15 UY UY0001034264A patent/UY34264A/es not_active Application Discontinuation
- 2012-08-15 AR ARP120102987A patent/AR087545A1/es unknown
- 2012-08-15 US US14/237,905 patent/US9067936B2/en not_active Expired - Fee Related
- 2012-08-15 HU HUE12748028A patent/HUE030106T2/en unknown
- 2012-08-15 EP EP12748028.3A patent/EP2744809B1/de active Active
- 2012-08-15 PE PE2014000167A patent/PE20141406A1/es not_active Application Discontinuation
-
2014
- 2014-01-16 IL IL230489A patent/IL230489A/en active IP Right Grant
- 2014-01-21 CO CO14011125A patent/CO6862151A2/es not_active Application Discontinuation
- 2014-02-13 CL CL2014000365A patent/CL2014000365A1/es unknown
- 2014-02-17 CR CR20140076A patent/CR20140076A/es unknown
- 2014-02-17 DO DO2014000031A patent/DOP2014000031A/es unknown
-
2015
- 2015-05-28 US US14/723,556 patent/US9416130B2/en not_active Expired - Fee Related
-
2016
- 2016-07-08 US US15/205,372 patent/US9610284B2/en not_active Expired - Fee Related
- 2016-12-08 HR HRP20161674TT patent/HRP20161674T1/hr unknown
- 2016-12-16 CY CY20161101310T patent/CY1118370T1/el unknown
-
2017
- 2017-01-04 SM SM201700005T patent/SMT201700005B/it unknown
- 2017-02-17 US US15/435,697 patent/US9861627B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN00568A (de) | ||
EA201391285A1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
PH12017502141A1 (en) | Compounds and their methods of use | |
TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
IN2014MN02598A (de) | ||
IN2014DN10386A (de) | ||
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
MY191358A (en) | Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer | |
IN2014MN00988A (de) | ||
GB201106750D0 (en) | Novel compounds | |
NZ706739A (en) | Substituted benzene compounds | |
IN2014MN01754A (de) | ||
CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
IN2014KN00769A (de) | ||
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
PH12015501609A1 (en) | Phenicol antibacterials | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
IN2014DN10670A (de) | ||
IN2015DN01151A (de) | ||
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
MX2016004934A (es) | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
IN2014MN01486A (de) | ||
IN2015DN02109A (de) | ||
GEP201706675B (en) | Imidazo-triazine derivatives as pde10 inhibitors |